SIREN L L C
Q4 2025 Form 13-F
GREENWICH, DELAWARE
CIK 0002005245
· Institutional investment manager
Consolidated report · includes
2 managers
since Q3 2024
$3.4B Reported Value Total
Reported value
$3.4B
Quarter over quarter
+25.1%
Holdings
113
Top-10 concentration
46.3%
Filing Structure
Reports holdings for
- Invus Financial Advisors LLC · File #028-19938 · since Q3 2024
- Invus Group, LLC (not a 13F filer in our records) · File #028-24462 · since Q3 2024
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Raymond Debbane
President
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2025 13F record
Q4 2025 13F filing summary
| Period of report | December 31, 2025 |
|---|---|
| Filed | February 13, 2026 |
| Form | 13F-HR |
| Reported value | $3.4B |
| Positions | 113 |
| Change in reported value | +31.1% |
| New positions | 26 |
| Exited positions | 28 |
| Position turnover | 38.3% |
| Top-10 concentration | 46.3% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 12, 2026
|
110 | $4.2B |
|
Q2 2026 13F
Filed Aug 13, 2026
|
115 | $4.9B |
|
Q1 2026 13F
Filed May 14, 2026
|
100 | $3.6B |
|
Q4 2025 13F
Filed Feb 13, 2026
|
113 | $3.4B |
|
Q3 2025 13F
Filed Nov 13, 2025
|
115 | $2.6B |
|
Q2 2025 13F
Filed Aug 13, 2025
|
110 | $1.9B |
|
Q1 2025 13F
Filed May 14, 2025
|
116 | $1.8B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
117 | $2.3B |
|
Q3 2024 13F
Filed Nov 13, 2024
|
109 | $2.0B |
Top 20 holdings · Q4 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | SRRK Scholar Rock Holding Corp | $476.8M | 14.22% |
| 2 | KYMR Kymera Therapeutics Inc | $255.7M | 7.63% |
| 3 | ONC BeOne Medicines AG | $151.9M | 4.53% |
| 4 | EWTX Edgewise Therapeutics Inc | $112.4M | 3.35% |
| 5 | RVMD Revolution Medicines Inc | $106.3M | 3.17% |
| 6 | CNTA Centessa Pharmaceuticals PLC | $100.7M | 3.0% |
| 7 | ARWR Arrowhead Pharmaceuticals Inc | $99.6M | 2.97% |
| 8 | BCAX Bicara Therapeutics Inc | $87.8M | 2.62% |
| 9 | OLMA Olema Pharmaceuticals Inc | $82.5M | 2.46% |
| 10 | IRON Disc Medicine Inc | $78.5M | 2.34% |
| 11 | GPCR Structure Therapeutics Inc | $75.0M | 2.24% |
| 12 | TNGX Tango Therapeutics Inc | $72.3M | 2.16% |
| 13 | RCUS Arcus Biosciences Inc | $71.7M | 2.14% |
| 14 | STOK Stoke Therapeutics Inc | $71.3M | 2.13% |
| 15 | CRNX Crinetics Pharmaceuticals Inc | $70.2M | 2.09% |
| 16 | DYN Dyne Therapeutics Inc | $68.5M | 2.04% |
| 17 | APLS Apellis Pharmaceuticals Inc | $64.8M | 1.93% |
| 18 | COGT Cogent Biosciences Inc | $57.9M | 1.73% |
| 19 | SEPN Septerna Inc | $55.8M | 1.66% |
| 20 | TSHA Taysha Gene Therapies Inc | $55.7M | 1.66% |
Values as reported on the Q4 2025 Form 13F. Every position is in the holdings table below.